Literature DB >> 9607615

The molecular pathobiology of cell membrane iron: the sickle red cell as a model.

P Browne1, O Shalev, R P Hebbel.   

Abstract

The molecular pathobiology of membrane-associated iron is clearly illustrated by the sickle red blood cell. The cytosolic aspect of the membranes of these cells carries several discrete iron compartments, including denatured hemoglobin and free heme, as well as molecular iron associated with membrane aminophospholipid and denatured globin. Affinity of the membrane for molecular iron is extraordinarily high and predicted to keep cytosolic free iron concentration < 10(-20) M. Membrane iron is bioactive and able to valence cycle, thus serving as a catalyst for generation of highly reactive hydroxyl radical. As a consequence of this oxidative biochemistry at the cytosol/membrane interface, multiple membrane defects arise that are of pathophysiologic importance. Thus, sickle red cells provide a pathobiologic paradigm for the membrane-damaging effect of iron-mediated targeting of oxidative damage at a sub-cellular level. This is relevant to a variety of biologic conditions accompanied by decompartmentalization of iron.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9607615     DOI: 10.1016/s0891-5849(97)00391-2

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  20 in total

Review 1.  Anaerobic storage of red blood cells.

Authors:  Tatsuro Yoshida; Sergey S Shevkoplyas
Journal:  Blood Transfus       Date:  2010-10       Impact factor: 3.443

Review 2.  Ascorbic acid: chemistry, biology and the treatment of cancer.

Authors:  Juan Du; Joseph J Cullen; Garry R Buettner
Journal:  Biochim Biophys Acta       Date:  2012-06-20

3.  Deterioration of red blood cell mechanical properties is reduced in anaerobic storage.

Authors:  Jennie M Burns; Tatsuro Yoshida; Larry J Dumont; Xiaoxi Yang; Nathaniel Z Piety; Sergey S Shevkoplyas
Journal:  Blood Transfus       Date:  2015-11-27       Impact factor: 3.443

4.  Derangement of erythrocytic AE1 in beta-thalassemia by caspase 3: pathogenic mechanisms and implications in red blood cell senescence.

Authors:  Silvana Ficarra; Ester Tellone; Bruno Giardina; Roberto Scatena; Annamaria Russo; Francesco Misiti; M Elisabetta Clementi; Deborah Colucci; Ersilia Bellocco; Giuseppina Laganà; Davide Barreca; Antonio Galtieri
Journal:  J Membr Biol       Date:  2009-02-24       Impact factor: 1.843

5.  Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies.

Authors:  Deepa Manwani; Paul S Frenette
Journal:  Blood       Date:  2013-09-19       Impact factor: 22.113

6.  Oxidative effects of gemfibrozil on anion influx and metabolism in normal and Beta-thalassemic erythrocytes: physiological implications.

Authors:  Ester Tellone; Silvana Ficarra; Bruno Giardina; Roberto Scatena; Annamaria Russo; M Elisabetta Clementi; Francesco Misiti; Ersilia Bellocco; Antonio Galtieri
Journal:  J Membr Biol       Date:  2008-09-29       Impact factor: 1.843

Review 7.  New insights into the pathophysiology and development of novel therapies for sickle cell disease.

Authors:  Scott Moerdler; Deepa Manwani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

Review 8.  Red blood cell storage lesion: causes and potential clinical consequences.

Authors:  Tatsuro Yoshida; Michel Prudent; Angelo D'alessandro
Journal:  Blood Transfus       Date:  2019-01       Impact factor: 3.443

9.  The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice.

Authors:  Robert P Hebbel; Gregory M Vercellotti; Betty S Pace; Anna N Solovey; Rahn Kollander; Chine F Abanonu; Julia Nguyen; Julie V Vineyard; John D Belcher; Fuad Abdulla; Shadé Osifuye; John W Eaton; Robert J Kelm; Arne Slungaard
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

Review 10.  State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.

Authors:  Latika Puri; Kerri A Nottage; Jane S Hankins; Doralina L Anghelescu
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.